FEATURE: GeneProt Hopes to Become the Celera of Proteomics, but Can it Fly Solo? | GenomeWeb

PARIS, Sept 12 - In July, Geneva Proteomics of Switzerland made a bold announcement, saying it planned to become the international leader in industrialized proteomics.

Armed with some of the leading brains in proteomics and $40 million in venture capital, the possibility that GeneProt would be able to conquer the market might have seemed feasible.

But on closer inspection many questions arise about how the company will achieve such an audacious goal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.